GAVI launches Advance Market Commitment to accelerate production of pneumococcal vaccines targeting needs of developing countries
Pneumococcal disease is one of the biggest vaccine preventable killers of children today, but now, thanks to the Advance Market Commitment (AMC), that's all about to change.
To accelerate the development and production of a new generation of pneumococcal vaccines, more targeted at the needs of developing countries and more affordable, GAVI, the World Bank and donors launched the pneumococcal Advance Market Commitment (AMC) in 2009.
Thanks to contracts between GAVI and two manufacturers, the Alliance and developing countries will pay a maximum US$3.50 per dose of pneumococcal vaccines procured in the coming years - more than 90% less than the cost of the same vaccines currently being sold in the European Union and United States.1
GAVI expects additional manufacturers from emerging markets to submit new pneumococcal vaccines for for participation in the AMC in the near future.
The AMC was designed to give manufacturers an incentive to invest in:
- finalising pneumococcal vaccines which include the additional serotypes required to combat the most common and fatal strains of the disease in low-income countries;
- increasing manufacturing capacity to provide the appropriate pneumococcal vaccines in sufficient quantities to meet demand.
At the same time, developing country governments can budget and plan for their immunisation programmes, knowing that vaccines will be available in sufficient quantity and at a price they can afford in the long-term.
PneumoADIP and AVI
Parallel to the AMC and to help developing countries lay the groundwork for introducing pneumococcal vaccines as soon as they become available, GAVI set-up the Accelerated Development and Introduction Plan for pneumococcal vaccine (PneumoADIP) in 2003.
The Alliance and the Pneumococcal AMC
- The World Bank: fiduciary support.
- Industrialised countries: the governments of Italy, the United Kingdom, Canada, Russia, Norway and the Bill & Melinda Gates Foundation committed a total US$1.5 bilion to launch the programme.
- GAVI committed to US$ 1.3 billion to support the cost of vaccines from 2010-2015, as well as programmatic and administrative support.
- WHO established the minimum technical criteria for the vaccines and provides technical assistance as required.
- UNICEF is responsible for vaccine procurement and distribution.
Based at the John Hopkins Bloomberg School of Public Health at Baltimore in the United States, the PneumoADIP worked to increase the understanding in low-income countries about the severity of pneumococcal disease and the need for immunisation.
Routine immunisation support
In the same year, following an investment case developed by the PneumoADIP, GAVI decided to offer financial support for the introduction of pneumococcal vaccines through its new and underused vaccine programme.
From 2010-2015, GAVI has endorsed up to US$ 1.3 billion to fund pneumococcal vaccines that are suitable for low-income countries through the AMC.
To be AMC eligible, vaccines must meet specific criteria developed by WHO and be approved by the Independent Assessment Committee (IAC) of the AMC.